請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/42332
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 李明學(Ming-Shyue Lee) | |
dc.contributor.author | Chih-Che Shen | en |
dc.contributor.author | 沈志哲 | zh_TW |
dc.date.accessioned | 2021-06-15T01:12:16Z | - |
dc.date.available | 2016-10-05 | |
dc.date.copyright | 2011-10-05 | |
dc.date.issued | 2011 | |
dc.date.submitted | 2011-08-16 | |
dc.identifier.citation | 1. Jemal, A., et al., Cancer Statistics, 2009. Ca-a Cancer Journal for Clinicians, 2009. 59(4): p. 225-249.
2. Sharma, S.V. and J. Settleman, ErbBs in lung cancer. Exp Cell Res, 2009. 315(4): p. 557-71. 3. Lippman, S.M., R.S. Herbst, and J.V. Heymach, Molecular origins of cancer: Lung cancer. New England Journal of Medicine, 2008. 359(13): p. 1367-1380. 4. Brambilla, E., et al., The new World Health Organization classification of lung tumours. Eur Respir J, 2001. 18(6): p. 1059-68. 5. National Institutes of Health, National Cancer Institute Web site. 2011. 6. Chambers, A.F., A.C. Groom, and I.C. MacDonald, Dissemination and growth of cancer cells in metastatic sites. Nat Rev Cancer, 2002. 2(8): p. 563-72. 7. Lauffenburger, D.A. and A.F. Horwitz, Cell migration: a physically integrated molecular process. Cell, 1996. 84(3): p. 359-69. 8. Thiery, J.P., Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer, 2002. 2(6): p. 442-54. 9. Netzel-Arnett, S., et al., Membrane anchored serine proteases: a rapidly expanding group of cell surface proteolytic enzymes with potential roles in cancer. Cancer Metastasis Rev, 2003. 22(2-3): p. 237-58. 10. Kawaguchi, T., et al., Purification and cloning of hepatocyte growth factor activator inhibitor type 2, a Kunitz-type serine protease inhibitor. J Biol Chem, 1997. 272(44): p. 27558-64. 11. Marlor, C.W., et al., Identification and cloning of human placental bikunin, a novel serine protease inhibitor containing two Kunitz domains. J Biol Chem, 1997. 272(18): p. 12202-8. 12. Muller-Pillasch, F., et al., Cloning of a new Kunitz-type protease inhibitor with a putative transmembrane domain overexpressed in pancreatic cancer. Biochim Biophys Acta, 1998. 1395(1): p. 88-95. 13. Qin, L., et al., Functional characterization of Kunitz domains in hepatocyte growth factor activator inhibitor type 2. FEBS Lett, 1998. 436(1): p. 111-4. 14. Delaria, K.A., et al., Characterization of placental bikunin, a novel human serine protease inhibitor. J Biol Chem, 1997. 272(18): p. 12209-14. 15. Parr, C., et al., The hepatocyte growth factor regulatory factors in human breast cancer. Clin Cancer Res, 2004. 10(1 Pt 1): p. 202-11. 16. Hamasuna, R., et al., Reduced expression of hepatocyte growth factor activator inhibitor type-2/placental bikunin (HAI-2/PB) in human glioblastomas: implication for anti-invasive role of HAI-2/PB in glioblastoma cells. Int J Cancer, 2001. 93(3): p. 339-45. 17. List, K. and C. Bergum, Loss of the Matriptase Inhibitor HAI-2 During Prostate Cancer Progression. Prostate, 2010. 70(13): p. 1422-1428. 18. Ng, I.O.L., et al., HAI-2 is epigenetically downregulated in human hepatocellular carcinoma, and its Kunitz domain type 1 is critical for anti-invasive functions. International Journal of Cancer, 2009. 124(8): p. 1811-1819. 19. Wu, Y.L., et al., Epigenetic inactivation and tumor suppressor activity of HAI-2/SPINT2 in gastric cancer. International Journal of Cancer, 2010. 127(7): p. 1526-1534. 20. Rutka, J.T., et al., An Epigenetic Genome-Wide Screen Identifies SPINT2 as a Novel Tumor Suppressor Gene in Pediatric Medulloblastoma. Cancer Research, 2008. 68(23): p. 9945-9953. 21. Yarden, Y. and M.X. Sliwkowski, Untangling the ErbB signalling network. Nature Reviews Molecular Cell Biology, 2001. 2(2): p. 127-137. 22. Wells, A., EGF receptor. Int J Biochem Cell Biol, 1999. 31(6): p. 637-43. 23. Mass, R.D., The HER receptor family: A rich target for therapeutic development. International Journal of Radiation Oncology Biology Physics, 2004. 58(3): p. 932-940. 24. Wells, A., EGF receptor. International Journal of Biochemistry & Cell Biology, 1999. 31(6): p. 637-643. 25. Hynes, N.E. and T. Schlange, Targeting ADAMS and ERBBs in lung cancer. Cancer Cell, 2006. 10(1): p. 7-11. 26. Warren, C.M. and R. Landgraf, Signaling through ERBB receptors: multiple layers of diversity and control. Cell Signal, 2006. 18(7): p. 923-33. 27. Grewal, T. and C. Enrich, Annexins - Modulators of EGF receptor signalling and trafficking. Cellular Signalling, 2009. 21(6): p. 847-858. 28. Hynes, N.E. and H.A. Lane, ERBB receptors and cancer: The complexity of targeted inhibitors (vol 5, pg 341, 2005). Nature Reviews Cancer, 2005. 5(7): p. -. 29. Burgess, A.W., et al., An open-and-shut case? Recent insights into the activation of EGF/ErbB receptors. Molecular Cell, 2003. 12(3): p. 541-552. 30. Citri, A. and Y. Yarden, EGF-ERBB signalling: towards the systems level. Nature Reviews Molecular Cell Biology, 2006. 7(7): p. 505-516. 31. Cappuzzo, F., et al., Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J Natl Cancer Inst, 2005. 97(9): p. 643-55. 32. Chou, T.Y., et al., Mutation in the tyrosine kinase domain of epidermal growth factor receptor is a predictive and prognostic factor for gefitinib treatment in patients with non-small cell lung cancer. Clin Cancer Res, 2005. 11(10): p. 3750-7. 33. Han, S.W., et al., Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib. J Clin Oncol, 2005. 23(11): p. 2493-501. 34. Janne, P.A., J.A. Engelman, and B.E. Johnson, Epidermal growth factor receptor mutations in non-small-cell lung cancer: implications for treatment and tumor biology. J Clin Oncol, 2005. 23(14): p. 3227-34. 35. Kosaka, T., et al., Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications. Cancer Res, 2004. 64(24): p. 8919-23. 36. Marchetti, A., et al., EGFR mutations in non-small-cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment. J Clin Oncol, 2005. 23(4): p. 857-65. 37. Mitsudomi, T., et al., Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence. J Clin Oncol, 2005. 23(11): p. 2513-20. 38. Shigematsu, H., et al., Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst, 2005. 97(5): p. 339-46. 39. Tsao, M.S., et al., Erlotinib in lung cancer - molecular and clinical predictors of outcome. N Engl J Med, 2005. 353(2): p. 133-44. 40. Yokoyama, T., et al., EGFR point mutation in non-small cell lung cancer is occasionally accompanied by a second mutation or amplification. Cancer Sci, 2006. 97(8): p. 753-9. 41. Herbst, R.S., J.V. Heymach, and S.M. Lippman, Lung cancer. N Engl J Med, 2008. 359(13): p. 1367-80. 42. Sorkin, A. and L.K. Goh, Endocytosis and intracellular trafficking of ErbBs. Experimental Cell Research, 2009. 315(4): p. 683-696. 43. Sorkin, A. and M. von Zastrow, Signal transduction and endocytosis: Close encounters of many kinds. Nature Reviews Molecular Cell Biology, 2002. 3(8): p. 600-614. 44. Moskowitz, H.S., C.T. Yokoyama, and T.A. Ryan, Highly cooperative control of endocytosis by clathrin. Molecular Biology of the Cell, 2005. 16(4): p. 1769-1776. 45. Grimes, M.L. and H.M. Miettinen, Receptor tyrosine kinase and G-protein coupled receptor signaling and sorting within endosomes. Journal of Neurochemistry, 2003. 84(5): p. 905-918. 46. Cavalli, V., M. Corti, and J. Gruenberg, Endocytosis and signaling cascades: a close encounter. Febs Letters, 2001. 498(2-3): p. 190-196. 47. Lu, Z., et al., Epidermal growth factor-induced tumor cell invasion and metastasis initiated by dephosphorylation and downregulation of focal adhesion kinase. Mol Cell Biol, 2001. 21(12): p. 4016-31. 48. Lu, Z.M., et al., Epidermal growth factor-induced tumor cell invasion and metastasis initiated by dephosphorylation and downregulation of focal adhesion kinase. Molecular and Cellular Biology, 2001. 21(12): p. 4016-4031. 49. Shibata, T., et al., Enhancing effects of epidermal growth factor on human squamous cell carcinoma motility and matrix degradation but not growth. Tumour Biol, 1996. 17(3): p. 168-75. 50. Voldborg, B.R., et al., Epidermal growth factor receptor (EGFR) and EGFR mutations, function and possible role in clinical trials. Annals of Oncology, 1997. 8(12): p. 1197-1206. 51. Chu, Y.W., et al., Selection of invasive and metastatic subpopulations from a human lung adenocarcinoma cell line. American Journal of Respiratory Cell and Molecular Biology, 1997. 17(3): p. 353-360. 52. Dong, W.J., et al., Epigenetic inactivation and tumor suppressor activity of HAI-2/SPINT2 in gastric cancer. International Journal of Cancer, 2010. 127(7): p. 1526-1534. 53. Yoda, T., et al., Expression of recombinant Norwalk-like virus capsid proteins using a bacterial system and the development of its immunologic detection. Journal of Medical Virology, 2000. 60(4): p. 475-481. 54. Hayhurst, A., Improved expression characteristics of single-chain Fv fragments when fused downstream of the Escherichia coli maltose-binding protein or upstream of a single immunoglobulin-constant domain. Protein Expression and Purification, 2000. 18(1): p. 1-10. 55. Riedl, E., et al., N-glycosylation of carnosinase influences protein secretion and enzyme activity: implications for hyperglycemia. Diabetes, 2010. 59(8): p. 1984-90. 56. De Luca, A., et al., The role of the EGFR signaling in tumor microenvironment. Journal of Cellular Physiology, 2008. 214(3): p. 559-567. 57. Gan, Y., et al., Differential roles of ERK and Akt pathways in regulation of EGFR-mediated signaling and motility in prostate cancer cells. Oncogene, 2010. 29(35): p. 4947-4958. 58. Zuo, J.H., et al., Activation of EGFR promotes squamous carcinoma SCC10A cell migration and invasion via inducing EMT-like phenotype change and MMP-9-mediated degradation of E-cadherin. J Cell Biochem, 2011. 59. Ogunwobi, O.O. and C. Liu, Hepatocyte growth factor upregulation promotes carcinogenesis and epithelial-mesenchymal transition in hepatocellular carcinoma via Akt and COX-2 pathways. Clin Exp Metastasis, 2011. 60. Choi, S.Y., et al., Role of TMPRSS4 During Cancer Progression. Drug News & Perspectives, 2008. 21(8): p. 417-423. 61. Generali, D., et al., Regulation of hepatocyte growth factor activator inhibitor 2 by hypoxia in breast cancer. Clin Cancer Res, 2007. 13(2 Pt 1): p. 550-8. 62. Hearn, M.T. and D. Acosta, Applications of novel affinity cassette methods: use of peptide fusion handles for the purification of recombinant proteins. J Mol Recognit, 2001. 14(6): p. 323-69. 63. Kirchhofer, D., et al., Hepsin activates pro-hepatocyte growth factor and is inhibited by hepatocyte growth factor activator inhibitor-1B (HAI-1B) and HAI-2. FEBS Lett, 2005. 579(9): p. 1945-50. 64. Kirchhofer, D., et al., Tissue expression, protease specificity, and Kunitz domain functions of hepatocyte growth factor activator inhibitor-1B (HAI-1B), a new splice variant of HAI-1. J Biol Chem, 2003. 278(38): p. 36341-9. 65. Yamauchi, M., et al., Hepatocyte growth factor activator inhibitor types 1 and 2 are expressed by tubular epithelium in kidney and down-regulated in renal cell carcinoma. J Urol, 2004. 171(2 Pt 1): p. 890-6. 66. Morris, M.R., et al., Tumor suppressor activity and epigenetic inactivation of hepatocyte growth factor activator inhibitor type 2/SPINT2 in papillary and clear cell renal cell carcinoma. Cancer Res, 2005. 65(11): p. 4598-606. 67. Parr, C. and W.G. Jiang, Hepatocyte growth factor activation inhibitors (HAI-1 and HAI-2) regulate HGF-induced invasion of human breast cancer cells. Int J Cancer, 2006. 119(5): p. 1176-83. 68. Fukai, K., et al., Hepatocyte growth factor activator inhibitor 2/placental bikunin (HAI-2/PB) gene is frequently hypermethylated in human hepatocellular carcinoma. Cancer Res, 2003. 63(24): p. 8674-9. 69. Betsunoh, H., et al., Clinical relevance of hepsin and hepatocyte growth factor activator inhibitor type 2 expression in renal cell carcinoma. Cancer Sci, 2007. 98(4): p. 491-8. 70. Tung, E.K., et al., HAI-2 is epigenetically downregulated in human hepatocellular carcinoma, and its Kunitz domain type 1 is critical for anti-invasive functions. Int J Cancer, 2009. 124(8): p. 1811-9. 71. Delaria, K.A., et al., Characterization of placental bikunin, a novel human serine protease inhibitor. Journal of Biological Chemistry, 1997. 272(18): p. 12209-12214. 72. Mendelsohn, J. and J. Baselga, The EGF receptor family as targets for cancer therapy. Oncogene, 2000. 19(56): p. 6550-6565. 73. Gazdar, A.F., Epidermal growth factor receptor inhibition in lung cancer: the evolving role of individualized therapy. Cancer Metastasis Rev, 2010. 29(1): p. 37-48. 74. Han, S.W., et al., Epidermal growth factor receptor (EGFR) downstream molecules as response predictive markers for gefitinib (Iressa, ZD1839) in chemotherapy-resistant non-small cell lung cancer. Int J Cancer, 2005. 113(1): p. 109-15. 75. Takeuchi, K. and F. Ito, EGF receptor in relation to tumor development: molecular basis of responsiveness of cancer cells to EGFR-targeting tyrosine kinase inhibitors. FEBS J, 2010. 277(2): p. 316-26. 76. Kubo, T., et al., MET gene amplification or EGFR mutation activate MET in lung cancers untreated with EGFR tyrosine kinase inhibitors. Int J Cancer, 2009. 124(8): p. 1778-84. 77. Engelman, J.A., et al., MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science, 2007. 316(5827): p. 1039-1043. 78. [Anon], MET amplification and resistance to EGFR-targeted small molecule therapies. Cancer Biology & Therapy, 2007. 6(5): p. 632-632. 79. Hsieh, H.L., et al., Thrombin Induces EGF Receptor Expression and Cell Proliferation via a PKC(delta)/c-Src-Dependent Pathway in Vascular Smooth Muscle Cells. Arteriosclerosis Thrombosis and Vascular Biology, 2009. 29(10): p. 1594-1601. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/42332 | - |
dc.description.abstract | 肺癌在全世界以及台灣是致死率最高的一類癌症,肺癌可以分為兩類:小細胞肺癌(small cell lung cancer)及非小細胞肺癌(non-small cell lung cancer)。非小型細胞肺癌經常在肺癌後期才容易被診斷出來,且伴隨著較差的預後。文獻指出蛋白酶失調與非小型細胞肺癌細胞移動與侵襲力增加有正關聯性。第二型肝細胞生長因子活化抑制者 (HAI-2)是一廣泛性絲胺酸蛋白酶抑制者,被認為可以有效地降低身經膠質瘤(glioma cancer)、前列腺癌(prostate cancer)以及胃癌(gastric cancer)的產生與惡化。在本篇實驗中,將探討HAI-2在前列腺癌細胞(PC-3)及非小型細胞肺癌(CL)細胞中,在細胞侵襲及移動力,以及調控表皮生長因子受體(EGFR)所扮演的角色。從結果顯示,在高侵襲性的PC-3及CL1-5細胞內,大量表達HAI-2蛋白能降低細胞移動及侵襲性。因為HAI-2是含有兩個功能區域的膜蛋白,我進一步利用大腸桿菌及人胚胎腎細胞(HEK293T)以及中國倉鼠卵巢癌細胞(CHO)表達HAI-2重組蛋白,並純化這些蛋白且分析這些蛋白對於CL1-5細胞的移動以及侵襲能力的影響。結果顯示大腸桿菌表達的重組蛋白,在高濃度作用下能抑制細胞的侵襲及移動。而由哺乳類細胞表達的重組蛋白在低濃度作用下,就能有效地抑制肺癌細胞侵襲力。除此之外,我也發現HAI-2具有兩個N-醣基化的胺基酸位置 (Asn57與Asn94),且醣基化會影響到HAI-2抑制肺癌細胞侵襲及移動的能力。同時,本篇也證實了HAI-2抑制肺癌細胞侵襲及移動能力,主要是透過HAI-2的kunitz domain 2。因為在非小型肺癌細胞惡化過程中,EGFR與HAI-2表現量有著逆向關聯性,我們更進一步證實了在CL1-5及PC-3細胞中,HAI-2的表達能降低EGFR蛋白的量,且此EGFR蛋白量的降低主要是藉由調控蛋白層次的機制而非影響基因的表達。
總結以上結果,本論文指出了HAI-2對於癌細胞侵襲及移動扮演著負向調控的角色,且HAI-2能調降在肺癌細胞中的EGFR蛋白的量。 | zh_TW |
dc.description.abstract | Lung cancer is the most lethal disease in the Taiwan and world. Lung cancer has different two types: small cell lung cancer and non-small cell lung cancer (NSCLC). NSCLC is often diagnosed at an advanced stage with poor prognosis. The dysregulation of cell surface proteolysis has been strongly implicated in the progression of NSCLC, particularly in cell invasion and metastasis. Hepatocyte growth factor activator inhibitor-2 (HAI-2) is a serine protease inhibitor and has been shown to be down-regulated in advanced human glioma, gastric and prostate cancers. In this study, I examined the role of HAI-2 in the cell invasion and migration of prostate cancer PC3 and NSCLC CL cells, as well as in modulating the protein level of EGFR. My results showed that the overexpression of HAI-2 in highly invasive CL1-5 and PC3 cells suppressed the cell invasion and migration. Since HAI-2 is a membrane-anchored protein with two extracellular functional domains, I used E.coli, mammalian HEK293T and CHO cells to express recombinant HAI-2 proteins, purified these proteins and analyzed the effects of HAI-2 recombinant proteins on CL1-5 cell invasion and migration. The results showed that the recombinant HAI-2 proteins from E. coli extracts suppressed CL1-5 cell invasion and migration within a high concentration, while a low concentration of the recombinant HAI-2 proteins purified from mammalian cell expression efficiently inhibited the cell migration and invasion. Moreover, I found that HAI-2 was glycosylated with two N glycosylation sites (Asn57 and Asn94) and the recombinant N57Q/N94Q HAI-2 proteins reduced its inhibitory effects on the cell migration and invasion, suggesting that the glycosylation was important for HAI-2 function. Furthermore, I showed that the kunitz domain 2 of HAI-2 played a major role in inhibiting NSCLC cell invasion and migration. Since EGFR is overexpressed and inversely correlated with HAI-2 expression during NSCLC progression, I further explored if HAI-2 was also involved in modulating the expression of EGFR in cancer cells and found that HAI-2 overexpression in CL1-5 and PC-3 cells was able to down regulate the EGFR protein but not the gene expression. The results taken together indicated that HAI-2 is a negative regulator for cancer cell migration and invasion, as well as to down regulate the EGFR protein levels. | en |
dc.description.provenance | Made available in DSpace on 2021-06-15T01:12:16Z (GMT). No. of bitstreams: 1 ntu-100-R98442010-1.pdf: 8524856 bytes, checksum: 62c033b4e1e3c310858709452135e054 (MD5) Previous issue date: 2011 | en |
dc.description.tableofcontents | 中文摘要 v
Abstract vii Chapter 1 1 Introduction 1 1.1 Lung cancer: 2 1.2 Extracellular proteases, cancer cell invasion and migration 3 1.3 Hepatocyte growth factor activator inhibitors type 2 (HAI-2) 3 1.4 Epidermal Growth Factor Receptor (EGFR) 5 1.5 Turnover and trafficking of EGFR 7 1.6 EGF signaling in cell invasion and migration 8 1.7 Research motivation and Purpose 9 Chapter 2 11 Materials and methods 11 2.1 Materials 12 2.2 Methods 16 Chapter 3 30 Results 30 3.1 Part I: Roles of HAI-2 in NSCLC cell migration and invasion 31 3.1.1 Inverse correlation between HAI-2 expression and cell migration and invasion in NSCLC cells 31 3.1.2 Inhibitory roles of HAI-2 in NSCLC cell migration and invasion 32 3.1.3 Effect of E.coli-expressed recombinant HAI-2 proteins on NSCLC cell migration and invasion 32 3.1.4 Identification of HAI-2 glycosylation sites in CL 1-5 cells 35 3.1.5 Roles of recombinant HAI-2 proteins from mammalian cell expression in NSCLC cell migration and invasion 36 3.1.6 Effect of the HAI-2 kunitz domain I and II on NSCLC invasion and migration 39 3.2 Part II: Roles of HAI-2 in down-regulation protein level of EGFR 41 3.2.1 The HAI-2 down-regulated and EGFR up-regulated in NSCLC progression 41 3.2.2 Restoration of HAI-2 expression in CL1-5 cells resulted in a reduction of both EGFR protein level and the EGF-induced cell invasion 41 3.3.3 Identification of which kunitz domain of HAI-2 was important for down-regulating EGFR. 42 3.3.4 HAI-2 overexpression reduced Erk1/2 or PI3K/AKT activity in PC-3 and CL1-5 cells 44 Chapter 4 45 Discussion 45 Chapter 5 52 Figures 52 Chapter 6 86 References 86 | |
dc.language.iso | en | |
dc.title | 第二型肝細胞生長因子活化抑制者在非小型肺癌中抑制癌細胞侵襲及調降表皮生長因子受器扮演的角色 | zh_TW |
dc.title | Role of hepatocyte growth factor activator inhibitor type 2 in inhibiting Non-small-cell lung carcinoma cell invasion and down-regulation of epidermal growth factor receptor | en |
dc.type | Thesis | |
dc.date.schoolyear | 99-2 | |
dc.description.degree | 碩士 | |
dc.contributor.oralexamcommittee | 李財坤,黃敏銓,詹迺立 | |
dc.subject.keyword | 第二型肝細胞生長因子活化抑制者,非小型細胞肺癌,表皮生長因子受體,肺癌,蛋白純化, | zh_TW |
dc.subject.keyword | HAI-2,NSCLC,lung cancer,EGFR,purification, | en |
dc.relation.page | 92 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2011-08-16 | |
dc.contributor.author-college | 醫學院 | zh_TW |
dc.contributor.author-dept | 生物化學暨分子生物學研究所 | zh_TW |
顯示於系所單位: | 生物化學暨分子生物學科研究所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-100-1.pdf 目前未授權公開取用 | 8.33 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。